See more : Talwalkars Healthclubs Limited (TALWGYM.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Verrica Pharmaceuticals Inc. (VRCA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Verrica Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- AKM Industrial Company Limited (1639.HK) Income Statement Analysis – Financial Results
- Wiz Co Participações e Corretagem de Seguros S.A. (WIZC3.SA) Income Statement Analysis – Financial Results
- Shefa Gems Ltd (SEFA.L) Income Statement Analysis – Financial Results
- Ajooni Biotech Limited (AJOONI.NS) Income Statement Analysis – Financial Results
- SDI Group plc (SDI.L) Income Statement Analysis – Financial Results
Verrica Pharmaceuticals Inc. (VRCA)
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.12M | 9.03M | 12.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 746.00K | 725.00K | 472.00K | 229.00K | 257.20K | 20.29K | 0.00 | 0.00 |
| Gross Profit | 4.38M | 8.31M | 11.53M | -229.00K | -257.20K | -20.29K | 0.00 | 0.00 |
| Gross Profit Ratio | 85.44% | 91.97% | 96.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.30M | 12.20M | 15.93M | 15.67M | 15.44M | 12.83M | 3.73M | 1.71M |
| General & Administrative | 0.00 | 17.41M | 26.98M | 24.51M | 14.64M | 9.05M | 727.00K | 204.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.31M | 17.41M | 26.98M | 24.51M | 14.64M | 9.05M | 727.00K | 204.00K |
| Other Expenses | 2.54M | -58.00K | 0.00 | -1.00K | 1.87M | -1.00K | 0.00 | 0.00 |
| Operating Expenses | 70.14M | 29.60M | 42.91M | 40.18M | 30.08M | 21.88M | 4.46M | 1.91M |
| Cost & Expenses | 70.88M | 30.33M | 42.91M | 40.18M | 30.08M | 21.88M | 4.46M | 1.91M |
| Interest Income | 2.74M | 476.00K | 123.00K | 521.00K | 1.88M | 1.23M | 0.00 | 0.00 |
| Interest Expense | 3.96M | 2.17M | 4.30M | 3.03M | 0.00 | 0.00 | 2.00K | 0.00 |
| Depreciation & Amortization | 836.00K | 718.00K | 472.00K | 229.00K | 257.20K | 20.29K | 4.46M | 1.91M |
| EBITDA | -62.20M | -21.60M | -30.31M | -39.43M | -30.08M | -20.63M | -4.46M | -1.91M |
| EBITDA Ratio | -1,213.84% | -231.16% | -256.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -65.76M | -21.30M | -30.91M | -40.18M | -30.08M | -21.88M | -4.46M | -1.91M |
| Operating Income Ratio | -1,283.35% | -235.78% | -257.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.24M | -3.19M | -4.17M | -2.51M | 1.87M | 1.23M | -2.00K | 0.00 |
| Income Before Tax | -67.00M | -24.49M | -35.08M | -42.69M | -28.21M | -20.65M | -4.46M | -1.91M |
| Income Before Tax Ratio | -1,307.47% | -271.11% | -292.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.19M | 3.82M | 2.80M | -257.00K | 1.23M | -4.46M | -1.91M |
| Net Income | -67.00M | -27.68M | -38.90M | -45.50M | -27.95M | -20.65M | -4.46M | -1.91M |
| Net Income Ratio | -1,307.47% | -306.44% | -324.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.10 |
| EPS Diluted | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.10 |
| Weighted Avg Shares Out | 45.34M | 34.16M | 27.04M | 25.00M | 24.90M | 14.66M | 19.95M | 19.95M |
| Weighted Avg Shares Out (Dil) | 45.34M | 34.16M | 27.04M | 25.00M | 24.90M | 14.66M | 19.95M | 19.95M |
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
WEST CHESTER, Pa., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced its development and commercialization partner, Torii Pharmaceutical Co....
Verrica Announces Pricing of $42.0 Million Public Offering
WEST CHESTER, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of an underwritten public offering of...
Verrica Announces Proposed Public Offering
WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell shares...
Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements
SAN FRANCISCO , Oct. 30, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Verrica Pharmaceuticals Inc. investors that the firm is investigating potential legal claims relating to the company's unsuccessful efforts in 2021 and 2022 to secure regulatory approval for...
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
- Posters to highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance -
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Verrica Pharmaceuticals Inc. (NasdaqGM: VRCA). In December 2020,...
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to focus on pediatricians and expand access beyond dermatologists WEST CHESTER, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc....
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
NEW ORLEANS , Sept. 27, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
WEST CHESTER, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, President and Chief Executive Officer...
Verrica Pharmaceuticals, Inc. (VRCA) Q2 2024 Earnings Call Transcript
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Kevin Gardner - Managing Director, LifeSci Advisors Ted White - President and Chief Executive Officer Joe Bonaccorso - Chief Commercial Officer Terry...
Source: https://incomestatements.info
Category: Stock Reports